LENSKART SOLUTIONS LTD LENSKART NIFTY_MIDNSEPHARMA

Healthcare · Medical Instruments & Supplies · India

https://www.lenskart.com

Lenskart Solutions Limited, a technology-driven eyewear company, engages in designing, manufacturing, branding, and retailing of eyewear products in India, Japan, Southeast Asia, and the Middle East. The company's products include prescription eyeglasses, sunglasses, goggles, screen glasses, and other products, such as contact lenses and eyewear accessories, including frames for men, women, and kids. It engages in lens manufacturing, lens edging, lens design, frame design, frame manufacturing, and delivery. The company operates as a direct-to-consumer company that designs and sells a wide range of eyewear products under the Lenskart and Owndays brands; and sub brands, including John Jacobs, Vincent Chase, Hooper, Lenskart Air, and Hustlr. It sells its products through online and offline channels, such as retail stores, websites, mobile applications, and other channels. The company also owns and operates eyewear retail stores in India and provides home eye check-up services. Lenskart Solutions Limited was incorporated in 2008 and is based in Gurugram, India.

Market & Price

Market Cap

₹90,580.77 Cr

Current Price

₹523.85

High / Low (52W)

₹549.20 / ₹400.15

Beta

Valuation

Stock P/E

181.89

Industry PE

37.60

Forward P/E

83.81

PEG Ratio

Book Value

₹37.92

Price to Book

13.81

P/S

10.28

EV/EBITDA

51.91

Dividend Yield

Profitability & Returns

ROCE

7.21%

ROE

6.65%

ROA

3.54%

Profit Margin

5.60%

Op Margin

9.97%

EPS (Latest Qtr)

₹1.16

EPS (TTM)

₹2.88

Balance Sheet & Liquidity

Debt/Equity

0.35

Quick Ratio

0.82

Current Ratio

2.26

Debt

₹3,096.60 Cr

Total Assets

₹14,413.32 Cr

Current Assets

₹5,670.43 Cr

Working Capital

₹3,162.87 Cr

Ownership

Promoter Holding

56.38%

Chg in Prom Hold

FII / Inst Holding

38.95%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹90,999.71 Cr

Total Revenue (TTM)

₹8,814.04 Cr

EBITDA

₹1,752.98 Cr

Free Cash Flow

₹-1,063.14 Cr

Operating Cash Flow

₹1,669.59 Cr

Shares Outstanding

₹172.91 Cr

Gross Margin

68.96%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

32.49%

Profit 5Y

66.99%

Revenue (YoY)

45.60%

Earnings (YoY)

-10.80%

PROS

Compounding revenue at 32.5% over 5 years.
Profit CAGR of 67.0% over 5 years.

CONS

Trading at a high P/E of 181.9.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA	523.85	181.89	₹90,580.77 Cr	-	7.21%	6.65%	32.49%	66.99%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Dec 2024	Mar 2025	Dec 2025	Mar 2026
Revenue	1,668.84 Cr	1,727.57 Cr	2,307.73 Cr	2,515.71 Cr
Cost of Revenue	547.56 Cr	560.44 Cr	717.01 Cr	764.46 Cr
Gross Profit	1,121.27 Cr	1,167.13 Cr	1,590.72 Cr	1,751.24 Cr
Operating Expenses	1,108.38 Cr	1,089.41 Cr	1,396.92 Cr	1,500.33 Cr
Operating Income	12.89 Cr	77.72 Cr	193.80 Cr	250.91 Cr
EBITDA	241.74 Cr	503.44 Cr	497.46 Cr	585.25 Cr
Interest Expense	34.47 Cr	47.51 Cr	48.71 Cr	43.54 Cr
Pretax Income	7.99 Cr	240.78 Cr	178.42 Cr	254.19 Cr
Tax Provision	6.14 Cr	20.65 Cr	45.71 Cr	50.58 Cr
Net Income	1.85 Cr	218.88 Cr	131.03 Cr	200.28 Cr
Diluted EPS	0.01	1.27	0.77	1.16

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2025	Mar 2026
Revenue	6,652.52 Cr	8,814.04 Cr
Cost of Revenue	2,134.40 Cr	2,735.67 Cr
Gross Profit	4,518.11 Cr	6,078.37 Cr
Operating Expenses	4,339.18 Cr	5,373.77 Cr
Operating Income	178.93 Cr	704.60 Cr
EBITDA	1,327.82 Cr	1,907.17 Cr
Interest Expense	145.89 Cr	178.45 Cr
Pretax Income	385.36 Cr	680.33 Cr
Tax Provision	88.02 Cr	179.38 Cr
Net Income	295.59 Cr	493.61 Cr
Diluted EPS	1.72	2.90

Compounded Sales Growth

5 Years:	32.49%
1 Year:	45.60%

Compounded Profit Growth

5 Years:	66.99%
1 Year:	-10.80%

Stock Price Performance

1 Year:	+29.96%
6 Months:	+26.24%
3 Months:	+8.12%
1 Month:	+1.53%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	-	-	14,413.32 Cr
Current Assets	-	-	-	5,670.43 Cr
Cash & Equivalents	-	-	-	973.30 Cr
Inventory	-	-	-	1,037.00 Cr
Receivables	-	-	-	174.72 Cr
Total Liabilities	-	-	-	5,561.58 Cr
Current Liabilities	-	-	-	2,507.56 Cr
Long Term Debt	-	-	-	133.57 Cr
Total Debt	-	-	-	3,096.60 Cr
Total Equity	-	-	-	8,738.51 Cr
Shares Outstanding	172.76 Cr	172.76 Cr	172.76 Cr	173.64 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2025	Mar 2026
Operating Cash Flow	-	1,669.59 Cr
Investing Cash Flow	-	-2,724.80 Cr
Financing Cash Flow	-	1,200.52 Cr
Capital Expenditure	-	-828.47 Cr
Free Cash Flow	-	841.13 Cr
Net Change in Cash	-	145.31 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2025	Mar 2026
Gross Margin %	67.9%	69.0%
Operating Margin %	2.7%	8.0%
Net Margin %	4.4%	5.6%
ROE %	-	5.6%
ROCE %	-	5.9%

Shareholding Pattern

Insiders

56.38%

Institutions

38.95%

Public Float

89.29%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LENSKART

No recent headlines available.

LENSKART · Healthcare